Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Observes selinexor with bortezomib and dexamethasone in adults with multiple myeloma

Collects real-world data on selinexor, bortezomib and dexamethasone in adults with multiple myeloma.

Plain-language title generated from the registry record
Registry title: Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

Key facts

Where
Florence, ItalySee the site

Where in Italy

  • Aou Careggi - Sod EmatologiaFlorence, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Gruppo Italiano Malattie EMatologiche dell'Adulto
Trial code
NCT06933277
Record updated
10 September 2025
Original description
This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy.Read full original descriptionShow less

Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone (SVd) for the Treatment of Multiple Myeloma Patients

This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy.

A minimum of 159 patients is required. Overall study duration is estimated in 36 months.

Inclusion: Age equal to or greater than 18 years old at the time of SVd initiation; Signed informed consent (if applicable); Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria; Relapse after one to three lines of therapy; Treatment with SVd, (i.e., having already received at least one dose) at the time the combination has entered clinical practice in Italy (AIFA authorization); Prior treatment with and refractoriness to lenalidomide.

Exclusion: Previous exposure to selinexor.

ClinicalTrials.gov NCT06933277